These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35631350)

  • 1. Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
    Chilamakuri R; Rouse DC; Agarwal S
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.
    Li Z; Yang C; Li X; Du X; Tao Y; Ren J; Fang F; Xie Y; Li M; Qian G; Xu L; Cao X; Wu Y; Lv H; Hu S; Lu J; Pan J
    J Cancer; 2020; 11(11):3274-3287. PubMed ID: 32231733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
    Chilamakuri R; Agarwal S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separase.
    Yim H; Erikson RL
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19742-7. PubMed ID: 21041660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.
    Liu Z; Rader J; He S; Phung T; Thiele CJ
    Cell Cycle; 2013 Jul; 12(14):2210-8. PubMed ID: 23892435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
    Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.
    Ismail IA; Kang KS; Lee HA; Kim JW; Sohn YK
    Eur J Pharmacol; 2007 Dec; 575(1-3):12-20. PubMed ID: 17706963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy.
    Chilamakuri R; Rouse DC; Yu Y; Kabir AS; Muth A; Yang J; Lipton JM; Agarwal S
    Transl Oncol; 2022 Jan; 15(1):101272. PubMed ID: 34823094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
    Mancini M; Monaldi C; De Santis S; Rondoni M; Papayannidis C; Sartor C; Curti A; Bruno S; Cavo M; Soverini S
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
    Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
    Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate.
    Abdelfatah S; Berg A; Huang Q; Yang LJ; Hamdoun S; Klinger A; Greten HJ; Fleischer E; Berg T; Wong VKW; Efferth T
    Acta Pharm Sin B; 2019 Sep; 9(5):1021-1034. PubMed ID: 31649851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G
    Giráldez S; Galindo-Moreno M; Limón-Mortés MC; Rivas AC; Herrero-Ruiz J; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
    FASEB J; 2017 Jul; 31(7):2925-2936. PubMed ID: 28360195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis.
    Czaplinski S; Hugle M; Stiehl V; Fulda S
    Oncotarget; 2016 Feb; 7(8):8700-11. PubMed ID: 26046302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.
    Serpico AF; D'Alterio G; Vetrei C; Della Monica R; Nardella L; Visconti R; Grieco D
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31200459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
    Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
    Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
    Garland LL; Taylor C; Pilkington DL; Cohen JL; Von Hoff DD
    Clin Cancer Res; 2006 Sep; 12(17):5182-9. PubMed ID: 16951237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.